Cary J. Claiborne - 18 Mar 2026 Form 3 Insider Report for NeuroSense Therapeutics Ltd. (NRSN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 15:36:17 UTC
Prior SEC filing
02 Jun 2025
Next SEC filing
09 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Cary Claiborne

Key filing fact

Cary J. Claiborne filed Form 3 for NeuroSense Therapeutics Ltd. (NRSN) on 18 Mar 2026.

Key facts

  • This page summarizes Cary J. Claiborne's Form 3 filing for NeuroSense Therapeutics Ltd. (NRSN).
  • 0 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Mar 2026, 15:36.

Change

  • Previous filing in this sequence was filed on 02 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001370930 Primary reporting owner

Claiborne Cary J

Relationship
Director
Address
C/O NEUROSENSE THERAPEUTICS LTD., 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, ISRAEL
Signature
/s/ Cary Claiborne
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRSN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
48,000
Date
18 Mar 2026
Ownership
Direct
NRSN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
60,000
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1
NRSN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
99,898
Date
18 Mar 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRSN holding Derivative

Options to Purchase Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
72,000
Exercise price
$1.43
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

Footnote F2

These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

Footnote F3

These options are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .